Аннотация
This study evaluates the incidence of the polymorphic forms of
mebendazole (MBZ) in tablets within the Brazilian market by dissolution
tests. The indicated dissolution medium by the USP 30 (United States
Pharmacopoeia) and a proposed modified medium were duly compared in
order to verify whether they are able to discriminate the polymorph A
from polymorph C in commercial tablets. Dissolution assay tests of
physical mixtures in raw materials of polymorph A and polymorph C, as
well as of nine tablets of MBZ (available in the Brazilian market), were
properly performed. For the dissolution tests, the USP 30 medium (I) and
a modified medium (II) were used. The modified medium allowed a
reproducible and reliable quality control of MBZ polymorphism in
commercial tablets.
Пользователи данного ресурса
Пожалуйста,
войдите в систему, чтобы принять участие в дискуссии (добавить собственные рецензию, или комментарий)